Gracell Biotechnologies (Shanghai) Co., Ltd.
Clinical trials sponsored by Gracell Biotechnologies (Shanghai) Co., Ltd., explained in plain language.
Clinical-stage biopharmaceutical company developing cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection aims to tame lupus when standard treatments fail Results expected Feb 2027 (estimated)
-
Experimental CAR t therapy takes aim at stubborn AL amyloidosis
Disease control Recruiting nowThis early-phase trial is testing a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to other therapies. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to attack two specific targets on the abnormal…
Phase 1 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Double-Pronged attack: new CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called GC012F for people with multiple myeloma that has come back or not responded to at least three prior treatments. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to recognize and attack myeloma cells using t…
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC